Conq Conqueri ering g Up Uppe per r Limb Limb Para Paraly - - PowerPoint PPT Presentation

Conq Conqueri ering g Up Uppe per r Limb Limb Para Paraly lysi sis s with with Wea Wearab rable e Me Medic dical al Robo Roboti tics cs

In Investor vestor Presen Presentation tation May ay 20 2019 19 Paul Paul R. . Gudo Gudonis nis, , Chairman hairman and and C CEO EO David avid He Henry, nry, CFO FO NYSE NYSE America merican: n: MYO

1

Legal Disclaimer

This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company’s management and its knowledge of the relevant

• market. The Company has tried, where possible, to identify such information and statements by using words such as

“anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and

• ther factors. These risks and uncertainties include, among others, risks related to the Company’s liquidity and financial

position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in Myomo's Form S-1 Registration Statement filed with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

2

Why Invest in MYO Now?

• Large Unmet Medical Need: Upper Extremity Paralysis
• Only Commercially-Available Device to Restore Function
• FDA Registered in US; CE Mark in Europe
• Reimbursed on Case-by-Case Basis by Commercial Payers; Approved by VA for Veterans
• Awaiting Coverage Policy & Payment by Medicare for New Codes Effective January 1st
• National Rollout Underway in US with Direct-to-Patient Marketing
• Increasing Pipeline; Higher ASP and Gross Margin
• Record Revenue and Gross Margin in 2018
• Significant Revenue Growth Expected in 2019

3

News Story

4

Current Upper Extremity Treatment Options

Rehabilitation

➢ Occupational Therapy ➢ Static Bracing ➢ Saebo ➢ Electrical Stimulation

(Bioness)

➢ Stationary Robotics

Medical

➢ Botox ➢ Baclofen

5

Brain Signal EMG Sensor

Signal Processing

Movement

MyoPro Orthosis: How it Works

6

CAUSES OF UPPER EXTREMITY PARALYSIS

STROKE BRACHIAL PLEXUS INJURY SPINAL CORD INJURY MULTIPLE SCLEROSIS TRAUMATIC BRAIN INJURY ALS

25% of 3M existing cases of upper extremity paralysis

$10 B Total US Market Size

25% of 350k new cases each year

$1.2 B New Incidences / Year +

US + EU + ROW

$30 B Estimate Includes:

Total US Market Potential Total Worldwide Market Potential

*Source: Christopher and Dana Reeve Foundation Survey, National Stroke Association, World Health Organization, and Myomo Base Model Estimates

Large Market Opportunity*

7

Myomo Commercialization + Scale-Up Timeline

8

2016 2017 2018 2019

Controlled Introduction Raising Growth Capital National Rollout and Direct to Patient Advertising

• IPO and Follow-on Offering

= $19.2 M

• MyoPro 2 Product Line
• CE Mark
• Applied to CMS for HCPCS

Codes

• Growing Pipeline
• Raised $5.6M
• International Distribution
• 400 Screening Days
• Pediatric Device Q4

Revenue = $1.0M Revenue = $1.6M Revenue = $2.4M Revenue = Q1 $830K 165%↑

Scaling Up

• MyoPro 1 Product Line
• Limited # of US Markets
• Clinical Research and Initial

Reimbursements

• VA Approval
• Chief Commercial Officer &

National Sales Team

• B2C Ads
• 200 Screening Days
• 2 HCPCS Codes Issued

Lower Limb Products Upper Limb Products Lower Limb Products Upper Limb Products

Exoskeletons Foot Drop

Only Commercially Available Upper Limb Product Line to Restore Function

Unit Volume

Orthotics Prosthetics

Stance Control

Competitive Landscape of O&P and Robotics

9

Wheelchair

PRODUCT and MFG.

Manufacturing and Distribution

DISTRIBUTION

EU Distributors

Centers of Excellence O&P Clinics

10

Direct Billing

Expanding O&P Distribution Footprint (Top 50 MSA’s)

11

Generating Leads with Digital Marketing

12

Facebook Ad Example #1

13

Facebook Ad Example #2

14

Organizing Screening Days Nationwide

15

Wichita, Kansas - Wednesday, May 22nd Lansing, Michigan - Thursday, May 23rd Boston, Massachusetts - Thursday, May 23rd Spokane, Washington - Friday, May 24th Portland, Maine - Friday, May 24th Traverse City, Michigan - Friday, May 24th

• St. Louis, Missouri - Friday, May 24th

Sacramento, California - Wednesday, May 29th Livonia, Michigan - Wednesday, May 29th Pittsburgh, Pennsylvania - Wednesday, May 29th New York City, New York - Wednesday, May 29th Nassau County, New York - Thursday, May 30th Bakersfield, California - Thursday, May 30th Springfield, Missouri - Thursday, May 30th Santa Clarita, California - Friday, May 31st Austin, Texas - Monday, June 3rd Hartford, Connecticut - Tuesday, June 4th Royal Oak, Michigan - Tuesday, June 4th Portland, Oregon - Tuesday, June 4th Chicago, Illinois - Tuesday, June 4th Madison, Wisconsin - Wednesday, June 5th Milwaukee, Wisconsin - Wednesday, June 5th Seattle, Washington - Thursday, June 6th Albany, New York - Thursday, June 6th Walnut Creek, California - Tuesday, June 11th San Francisco, California - Wednesday, June 12th Boston, Massachusetts - Wednesday, June 12th San Jose, California - Thursday, June 13th Ann Arbor, Michigan - Thursday, June 13th Traverse City, Michigan - Friday, June 14th East Lyme, Connecticut - Tuesday, June 18th Salt Lake City, Utah - Wednesday, June 19th Livonia, Michigan - Wednesday, June 19th Boston, Massachusetts - Thursday, June 20th Spokane, Washington - Friday, June 21st Grand Rapids, Michigan - Friday, June 21st

• St. Louis, Missouri - Monday, June 24th

Sacramento, California - Tuesday, June 25th Southern New Jersey - Tuesday, June 25th Detroit, Michigan - Tuesday, June 25th Bakersfield, California - Tuesday, June 25th Nassau County, New York - Wednesday, June 26th Clinton Township, Michigan - Wednesday, June 26th Santa Clarita, California - Thursday, June 27th Which screening day would you like to attend? New York Area - Multiple Dates Austin, Texas - Monday, May 6th Portland, Oregon - Tuesday, May 7th Royal Oak, Michigan - Tuesday, May 7th Raleigh, North Carolina - Wednesday, May 8th Southern Vermont - Thursday, May 9th Ann Arbor, Michigan - Thursday, May 9th Seattle, Washington - Thursday, May 9th Belleville, Illinois - Thursday, May 9th Warner Robins, Georgia - Monday, May 13th Southern New Jersey - Tuesday, May 14th Minneapolis, Minnesota - Tuesday, May 14th Los Angeles, California - Wednesday, May 15th San Francisco, California - Wednesday, May 15th San Jose, California - Thursday, May 16th Munster, Indiana - Thursday, May 16th Houston, Texas - Friday, May 17th Grand Rapids, Michigan - Friday, May 17th Columbia, Missouri - Friday, May 17th Walnut Creek, California - Tuesday, May 21st Salt Lake City, Utah - Wednesday, May 22nd

More Screening Days Growing Patient Pipeline

16

20 40 60 80 100 120 140 Q1 Q2 Q3 Q4 Q1

Screening Days in 2018-2019

.

Strong Growth in Quarterly Revenues (YoY)

17

100,000 200,000 300,000 400,000 500,000 600,000 700,000 800,000 900,000 1,000,000

1Q 2Q 3Q 4Q 2016 2017 2018 2019 +25% +63% +165% +106%

… And Increased ASP and Gross Margin %

Q1 2018 Q1 2019

$23,700 $22,000 ASP

18

Q1 2018 Q1 2019

79% 65%

Catalysts: Product Mix / Channel / Direct Billing

GM%

Product Development to Expand Market

ADULTS (MyoPro2 JUNE 2017) ADOLESCENTS (JUNE 2018) PEDIATRICS (2019E)

19

Reimbursement by Various Payers

20

Approvals on Case by Approved for Vets Issued New Case Basis HCPCS Codes Billed by O&P Provider 40+ VAMC’s Pending Coverage and Payment Amt. New Direct Billing Commercial Payers Military Medicare

Growing # MyoPro Units in Reimbursement Process

21

6/30/18

Previous Cases Pending Reimbursement 92 222 167 243 139 111 92 222 306 354 Screening Insurance Authorization Order

9/30/18 12/31/18 3/31/19

New Unit Adds in Q1

22

More Patient Cases Progressing through the Reimbursement Process

112 203 194 151 Q4 2018 Q1 2019

Total # of Cases Post Evaluation/Pre Submission Total # of Cases with Pre-Authorization Submitted and Pending Approval

306 354

Entering International Markets

23 23

European Target Countries

• Established Myomo Business

Development Office in Europe

• Recruited O&P Providers in Germany,

Denmark, UK, Italy

• Conducting Screening Days and Building

Patient Pipeline

24 24

Setting The Stage For a Strong 2019

25

Expect to grow revenues significantly in 2019

Revenue Gross Margin

313 830 Q1'18 Q1'19 165% 65% 79% Q1'18 Q1'19 000’s

Investments to Support Revenue Growth

26

Begin to drive operating leverage in the business in 2019

Investments in:

• Product Development
• Marketing and Clinical Support
• Reimbursement Team

Operating Expenses

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19

Cash Position

27

Current burn rate $800K - $1M per month Generate operating leverage in 2019 to start to reduce the cash burn

• 3.5
• 3.0
• 2.5
• 2.0
• 1.5
• 1.0
• 0.5

0.0

Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19

$ Millions

Operating Cash Flow

Seasonal reduction in liabilities

2019 Cash Guidance

28

• We believe our cash balance at March 31, 2019 is sufficient to

fund operations and capital expenditure requirements in 2019.

• Beyond 2019, we believe additional capital is required to

achieve our breakeven target. Cash Balance Q1’19 - $9.2M

Investor Summary: Catalysts for Growth

29

MYO Current Base #1: Increased US Distribution & Direct-to-Patient Marketing = More Demand # 2: New Product Development = More Target Patients #3: Medicare Reimbursement Potential = Greater Patient Access #4: International Markets = More Population